AMT Medical, an Ede and Utrecht, the Netherlands-based clinical-stage medtech company, raised $25M in Series B funding.
The round was led by Bender Analytical Holding B.V. (BAH). Other investors Invest-NL, and the European Innovation Council (EIC) Oost NL and angels also participated.
The company intends to use the funds to support new key initiatives, including CE marking and initial clinical trials in the United States in open and robotic settings.
Led by CEO Rutger Tulleken, AMT Medical is a clinical-stage medtech company spun out of neurovascular ELANA technology which was earlier brought to the market (CE and FDA). With 27 employees and ISO 13485-certification, it holds over 40 patents for its beating-heart surgical platform. The ELANA® Heart Bypass System is a minimally invasive solution designed to replace traditional open-heart bypass surgery, leading to robot-assisted keyhole surgery compatible with surgical robots.
Following this financing round, the capital will drive AMT’s running initiatives: Completing AMT Medical’s European first-in-human trial evaluating the system during – still – open chest CABG procedures with a beating heart.
FinSMEs
17/04/2025